{
    "Trade/Device Name(s)": [
        "EASYMAX Tag Self-Monitoring Blood Glucose System"
    ],
    "Submitter Information": "EPS Bio Technology Corp.",
    "510(k) Number": "K201258",
    "Predicate Device Reference 510(k) Number(s)": [
        "K121207"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "September 1, 2021",
    "Summary Letter Received Date": "January 22, 2021",
    "Submission Date": "January 20, 2021",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "EASYMAX Tag Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical biosensor"
    ],
    "Methodologies": [
        "Enzyme-based glucose detection (FAD-GDH)"
    ],
    "Submission Type(s)": [
        "System",
        "Analyzer",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for EASYMAX Tag Self-Monitoring Blood Glucose System, an OTC electrochemical glucose meter with NFC-enabled data transfer",
    "Indications for Use Summary": "Quantitative measurement of glucose in fresh capillary whole blood from fingertip, palm, or forearm for at-home (OTC) self-testing by a single patient with diabetes, not for neonates, diagnosis, or screening.",
    "fda_folder": "Clinical Chemistry"
}